Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 6/20 | 0.52 |
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA9 | Q16790 | 6/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16059373 | 1.00 | KDM4E (0.59) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL31550272 | 0.77 | MAOA (0.41) | KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL15549753 | 0.77 | MAOA (0.41) | KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL22640129 | 0.77 | KDM4E (0.71) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL22639981 | 0.77 | KDM4E (0.71) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL16058956 | 0.77 | KDM4E (0.71) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL16059747 | 0.77 | KDM4E (0.71) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL16058509 | 0.77 | KDM4E (0.71) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL5354594 | 0.75 | CA12 (0.60) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL22640088 | 0.75 | KDM4E (1.00) | KDM4EADRB3ADRB2ADRB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190135819-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-05-09 | — | — | US | disclosed |
| US-10118931-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180282343-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-10-04 | — | — | US | disclosed |
| US-9856267-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2017-11-09 | — | — | US | disclosed |
| US-9738651-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2016044641-A2 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM4E 1082/4885CA12 4169/4885CA1 3865/4885 |
| US-10118931-B2 | CARM1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | KDM4E 1082/4885CA12 4169/4885CA1 3865/4885 |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM4E 1082/4885CA12 4169/4885CA1 3865/4885 |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM4E 1077/4885CA12 4183/4885CA1 3881/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | KDM4E 1077/4885CA12 4183/4885CA1 3881/4885 |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | KDM4E 1082/4885CA12 4169/4885CA1 3865/4885 |
| US-20190135819-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM4E 1082/4885CA12 4169/4885CA1 3865/4885 |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM4E 1082/4885CA12 4169/4885CA1 3865/4885 |
| US-20180282343-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM4E 1077/4885CA12 4183/4885CA1 3881/4885 |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM4E 1195/4885CA12 4199/4885CA1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.